Valuation: KalVista Pharma

Market Cap 1.44B 1.25B 1.17B 1.07B 2B 137B 2.04B 13.75B 5.37B 68.68B 5.4B 5.28B 229B P/E 2024
-2.46x
P/E 2025 -5.3x
Enterprise Value 1.42B 1.23B 1.16B 1.05B 1.98B 136B 2.01B 13.6B 5.31B 67.91B 5.34B 5.22B 227B EV / Sales 2024
-
EV / Sales 2025 10.9x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+0.04%
3 months+0.75%
6 months+81.09%
Current year+67.18%
Current year 14.22
Extreme 14.22
27
1 year 10.41
Extreme 10.41
27
3 years 7.21
Extreme 7.21
27
5 years 4.12
Extreme 4.12
27
10 years 0
Extreme 0
45
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/11/2016
Chief Executive Officer 61 06/03/2024
President - 11/06/2026
Director TitleAgeSince
Chairman - 11/06/2026
Date Insider Type Main position Quantity % Market Cap.
2/21/26 A Fiscal year

Executive/Senior Manager

18,097 0.0358%
2/21/26 A Fiscal year

Chief Technology Officer

27,854 0.0551%
2/21/26 A Fiscal year

Chief Financial Officer

11,767 0.0233%

Financials

2024 2025
Net sales - 73.62M 63.81M 59.82M 54.54M 103M 7.03B 104M 704M 275M 3.52B 276M 270M 11.73B
Net income -127M -110M -103M -93.83M -177M -12.09B -179M -1.21B -473M -6.05B -475M -465M -20.18B -164M -142M -133M -122M -229M -15.68B -233M -1.57B -614M -7.85B -617M -603M -26.18B
Net Debt -203M -176M -165M -150M -283M -19.38B -288M -1.94B -759M -9.7B -762M -746M -32.37B -16.01M -13.87M -13.01M -11.86M -22.31M -1.53B -22.67M -153M -59.79M -765M -60.1M -58.79M -2.55B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. KALV Stock